Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
SonoThera›
Analysis
AddedFeb 17, 2024
UpdatedJun 18, 2026
SonoThera

SonoThera

Series B

SonoThera is a biotechnology company developing ultrasound-mediated nonviral genetic medicines for diseases including Duchenne muscular dystrophy and hemophilia A.

HQ
South San Francisco, CA, US
Founded
2021
Loading
Overview
Analysis
Compare
Fundraising
Employees
News
Website

Contents

  1. 01Products & Services
  2. 02Market Outlook
  3. 03Competitive Strengths
  1. 01Products & Services
  2. 02Market Outlook
  3. 03Competitive Strengths

Product Overview

SonoThera develops the RIPPLE platform, a nonviral ultrasound-mediated gene delivery system that pairs intravenously injected ultrasound enhancing agents with externally applied therapeutic ultrasound to transport DNA and RNA payloads into targeted tissues. The platform supports full-length transgenic proteins, gene editors, siRNAs, and antisense oligonucleotides, and has been demonstrated preclinically in liver, heart, skeletal muscle, kidney, and brain.

The pipeline targets Duchenne muscular dystrophy with full-length dystrophin delivery, autosomal dominant polycystic kidney disease, X-linked Alport syndrome, and hemophilia A. SonoThera holds exclusive licenses from GE HealthCare for the Optison and Sonazoid microbubble products and has stated plans to initiate its first clinical trial in DMD in 2027.

Market Outlook

SonoThera operates in the genetic medicine market alongside viral vector and lipid nanoparticle platforms used in approved gene and cell therapies. Existing approaches face constraints in payload size, organ targeting beyond liver, redosing, immunogenicity, and cost, leaving many monogenic and large gene targets, including Duchenne muscular dystrophy, hemophilia, and kidney disease, without durable nonviral options.

Nonviral ultrasound-mediated delivery aims to broaden the addressable patient population by enabling multi-organ targeting and repeat dosing of large genetic payloads. Industry interest is reflected in SonoThera ASGCT, ASH, ASN, and MDA presentations and in strategic investment by ARCH Venture Partners, Vida Ventures, Illumina Ventures, Johnson and Johnson, Eli Lilly, Leaps by Bayer, Otsuka, UCB Ventures, and Vivo Capital.

Competitive Advantages

SonoThera differentiates from viral vector and lipid nanoparticle approaches by using ultrasound and microbubble enhancing agents to deliver DNA and RNA payloads without size restrictions and with broad biodistribution across organs including liver, heart, muscle, kidney, and brain. The platform is redosable, allows tunable acoustic profiles for tissue targeting, and is designed to avoid the immunogenicity and toxicity associated with AAVs and LNPs.

The approach builds on more than 35 million annual ultrasound enhancing agent doses already used safely in U.S. cardiac imaging and is backed by exclusive licenses to the GE HealthCare microbubble products Optison and Sonazoid. SonoThera has integrated payload design and manufacturing for DNA, RNA, siRNA, and gene editors in-house, supporting multiple parallel disease programs.